Neumora Therapeutics, Inc. - 10-Q Filing

Neumora Therapeutics reports Q3 2025 financial results including research and development expenses and updates on licensing agreements.

SEC EDGAR ·

Tickers: $NMRA

Read the full article at SEC EDGAR

More Regulatory news